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ABSTRACT 
Pancreatic neuroendocrine tumours (PanNETs) are rare neoplasms 
accounting for 1-2% of all pancreatic tumours. The biological behaviour of 
PanNETs is heterogeneous and unpredictable, adding to the difficulties of 
clinical management. The DAXX (death domain associated protein) and 
ATRX (alpha-thalassemia/mental retardation syndrome X-linked) genes 
encode proteins involved in SWI/SNF-like chromatin remodelling. Somatic 
inactivating mutations in DAXX and ATRX are frequent in PanNETs, mutually 
exclusive, and associated with telomere dysfunction resulting in genomic 
instability and alternate lengthening of telomeres. We sought to assess the 
clinical significance of the loss of the ATRX and DAXX proteins as determined 
by immunohistochemistry (IHC) in patients with PanNET.   
From an unselected cohort of 105 patients, we found ATRX loss in 10 
tumours (9.5%) and DAXX loss in 16 (15.2%). DAXX and ATRX loss were 
confirmed mutually exclusive and associated with other adverse 
clinicopathological variables and poor survival in univariate analysis. In 
addition ATRX loss was also associated with higher AJCC stage and 
infiltrative tumour borders. However only ATRX loss, lymphovascular invasion 
and perineural spread were independent predictors of poor overall survival in 
multivariate analysis.   
In conclusion, loss of expression of ATRX as determined by IHC is a useful 
independent predictor of poor overall survival in PanNETs. Given its relative 
availability, ATRX loss as determined by IHC may have a role in routine 
clinical practice to refine prognostication in patients with PanNET. 
Keywords: ATRX, DAXX, Pancreatic neuroendocrine tumour 
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INTRODUCTION 
 
Pancreatic neuroendocrine tumours (PanNETs) are relatively rare neoplasms 
of the pancreas, accounting for 1 to 2% of all pancreatic neoplasms and 
occurring in 1 per 100,000 individuals per year [1]. PanNETs are usually 
sporadic, however they can be associated with inherited predisposition 
syndromes, most commonly multiple endocrine neoplasia 1 (MEN1), von 
Hippel-Lindau syndrome (VHL), neurofibromatosis type 1 (NF-1) and tuberous 
sclerosis [2]. PanNETs may be either ‘functional’ and secrete hormones that 
cause clinical symptoms/signs, or ‘non-functional’ and grow silently.  
 
PanNETs are most commonly low grade malignancies and the 10-year overall 
survival for patients with PanNET has been reported to range from 40% to 
50% [3,4]. However, the biological behaviour of PanNETs in individual 
patients is quite variable.  Whilst some tumours may grow slowly and not 
recur even after marginal excision by enucleation alone, others may behave 
aggressively and rapidly metastasise [5]. Widely accepted predictors of long-
term survival include histological grade based on the proliferative rate as 
determined by mitotic count and Ki67 proliferative index, functional status and 
TNM staging [6,7]. These tools are useful at a population level and currently 
implemented into routine clinical practice, however it remains difficult to 
predict at the individual patient level which tumours will recur and behave 
aggressively. 
 
Recent genomic studies have shed light on the molecular pathogenesis of 
PanNETs and hold promise to predict outcome [8]. Mutually exclusive somatic 
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inactivating mutations in either the DAXX (death-domain-associated protein) 
or ATRX (alpha-thalassemia/mental retardation syndrome X-linked) genes 
have been reported in up to 33% to 43% of PanNETs in some series [8,9]. 
The ATRX and DAXX proteins encoded by these genes bind with each other 
to form a histone chaperone complex involved in depositing histone variant 
H3.3 at the telomeres and pericentric heterochromatin regions of the genome 
[10,11]. Loss of function of either of these proteins leads to telomere 
dysfunction and results in impaired non-homologous end joining, alternate 
lengthening of telomeres (ALT) and general genomic instability [12-14].   
 
Somatic mutations of ATRX or DAXX may be either homozygous or 
heterozygous, but heterozygous mutation (that is, mutation of a single allele) 
is associated with loss of protein expression as determined by 
immunohistochemistry (IHC) [9]. The hypothesised mechanisms of second 
allele inactivation in heterozygous mutation include epigenetic silencing of 
DAXX and X chromosome inactivation involving ATRX. Recent literature on 
the prognostic value of DAXX and ATRX protein expression as determined by 
IHC has been somewhat contradictory [9,15-18]. Although the majority of 
studies have suggested that DAXX and ATRX loss alone or the combination 
of either DAXX or ATRX loss is associated with poor outcome, this has not 
been a consistent finding and others have not found this association [15]. 
ATRX IHC is becoming increasingly available in routine clinical practice, 
because of its role in subclassifying glioblastoma.  If ATRX or DAXX loss can 
be proven to be consistently associated with poor survival in independent 
cohorts, IHC for these proteins may be rapidly deployed into routine clinical 
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practice.  We therefore sought to investigate the clinical and pathological 
associations of ATRX and DAXX expression as assessed by IHC in a large, 
unselected and independent cohort of patients with PanNET.  
 
MATERIAL AND METHODS 
We searched the computerised database of the Department of Anatomical 
Pathology, Royal North Shore Hospital, Sydney Australia for all patients 
undergoing surgical resection for PanNETs between January 1992 and 
August 2016.  Cases which underwent needle biopsy alone rather than 
resection by enculeation or standard pancreatectomy procedures were 
excluded. All cases were independently reviewed by a pathologist (AG) 
experienced in the diagnosis of PanNET to definitively confirm the diagnosis 
and grade according to the 2017 World Health Organization (WHO) 
classification [7].   High grade pancreatic neuroendocrine carcinomas (that is 
Grade 3 PanNEC under the WHO 2017 classification) were excluded.  
However cases with low grade cytological features but high proliferative 
indices (that is Grade 3 PanNET under the WHO 2017 classification) were 
included. Mixed tumours with a pancreatic ductal adenocarcinoma, squamous 
or acinar component (MiNEN under the WHO 2017 classification) were also 
excluded.  For patients with multiple tumours, the largest tumour was 
assessed. 
  
Tissue microarrays (TMA) were created from formalin fixed paraffin 
embedded (FFPE) blocks so that they contained two separate 1 mm cores of 
tumour tissue.  Overall survival was obtained from medical records and 
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publicly available death notices and defined as the duration alive from the 
time of definitive tissue diagnosis until the date of audit in July 2017.   
 
Immunohistochemistry for DAXX and ATRX was performed on TMA slides 
using commercially available rabbit polyclonal antibodies. For DAXX (Sigma 
Aldrich, HPA 008736, dilution 1:100) and for ATRX (Sigma Aldrich, HPA 
001906, dilution 1:200) antibodies were used after antigen retrieval in a high 
pH solution at 97°C for 30 mins for DAXX and 40 mins for ATRX.  The TMA 
slides were sectioned at 4μm thickness onto positively charged slides 
(Superfrost plus; Menzel-Glaser, Germany) and the slides were stained on an 
automated platform, Leica Bond AR9640.  A biotin-free polymer based 
detection system (Leica Bond Polymer Define Detection, Cat. No. DS9713) 
was used. 
 
Immunohistochemistry was interpreted by a single pathologist (AG) who was 
blinded to all clinical and pathological data at the time of analysis.  DAXX and 
ATRX expressions (illustrated in Figure 1) were classified as either positive, 
defined as unequivocal nuclear staining in tumour cells; or negative, defined 
as completely absent nuclear staining in the presence of an unequivocal 
internal positive control provided by non-neoplastic cells with retained nuclear 
expression (for example lymphocytes, endothelial cells or stromal cells). 
Cytoplasmic staining was considered non-specific and disregarded.  If there 
was difficulty in confidently assessing the results of IHC on the TMA cores (for 
example if tumour cells were negative but there were no convincing internal 
positive controls) then staining was repeated on whole sections. 
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Of the 113 patients with PanNET, the results of DAXX and ATRX expression 
were available for 104 and 105 patients respectively.  For 8 patients both 
DAXX and ATRX results were unavailable, due to the lack of tumour cells on 
the TMA sections or absent internal positive controls even on whole stained 
sections. For one patient ATRX was assessable, but DAXX status could not 
be assessed due to repeatedly absent internal positive controls on whole 
sections.  For most cases (n= 83) the Ki67 proliferative index was based on 
whole sections reported at the time of diagnosis.  For cases where the ki67 
proliferative index was not evaluated at the time of routine reporting and only 
TMA specimens were available (n= 29) the ki67 index was determined based 
on the TMA cores only. For 2 cases the ki67 index could not be determined 
due to insufficient material present in the TMA. 
 
Statistical analysis was performed using IBM SPSS Statistics v23 on OSX 
and P values of <0.05 were considered as statistically significant.  Mean 
survival was estimated using Kaplan-Meier methods and the significance of 
the differences was tested using the log-rank test.  Five and ten-year survival 
rate was estimated using life tables.  Multivariable Cox regression proportional 
hazards analysis was used to explore the effect of DAXX and ATRX IHC 
status on overall survival adjusted for clinicopathological variables analysed 
with a p value of <0.05.  This study was approved by the Northern Sydney 
Local Health District Human Research Ethics Committee – ref: 
LNR/13/Hawke/424  
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RESULTS 
A total of 113 eligible patients who underwent surgical resections for PanNET 
were identified. The clinical and pathological features are presented in Table 
1.   Briefly, 47% were female; the median age at diagnosis was 58 years 
(range 18-87 years); 85% underwent partial pancreatectomy whereas 15% 
had enucleation surgery only; 59% were located in the body or tail and 35% in 
the head of the pancreas; 19% had multiple tumours resected; the median 
size of the tumour or largest tumour if multiple was 13mm (range 2-45mm); 
5% showed coagulative necrosis; 56% were WHO 2017 grade 1, 42% grade 
2 and 2% grade 3; 25% had nodal involvement at diagnosis; 65% were AJCC 
stage I or II tumours at presentation; 13% had known distant metastasis at 
presentation; 88% were completely resected with clear margins;  73% had a 
circumscribed/pushing tumour border; 30% had lymphovascular invasion; 7% 
had perineural spread; 21% were known to be hormone secreting clinically 
and 16% were associated with confirmed hereditary syndromes with 
predisposition to developing PanNET (usually MEN1).   
 
The mean overall survival (OS) was 206 months.  Features associated with 
worse overall survival included location in the head of pancreas (p = 0.005), 
the presence of coagulative necrosis (p = 0.022), an infiltrative tumour border 
(p = 0.001), the presence of lymphovascular invasion (p = 0.028), and the 
presence of perineural invasion (p = 0.025).  Ki67 (p = 0.788), mitotic activity 
(p = 0.893), WHO grade (p = 0.414) and size (p = 0.648) were all not 
predictive of OS. 
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ATRX was found to be negative in 10 (10%) and positive in 95 (90%) cases.   
For DAXX, 16 (15%) cases were DAXX-negative, 88 (85%) cases were 
DAXX-positive.  ATRX and DAXX loss were mutually exclusive in tumours 
and either ATRX or DAXX loss was present in 25% of tumours.  The 
relationship between ATRX/DAXX loss and survival is presented in Table 2.  
Briefly, when analysed as a group, tumours which were either ATRX or 
DAXX-negative were associated with poorer overall survival (OS) than 
tumours with retained expression of both markers (mean 162 months versus 
231 months, p=0.045, Figure 2A). However, when ATRX and DAXX were 
analysed separately, ATRX loss alone remained predictive of poor OS (103 
months versus 226 months, p=0.0001, Figure 2B), whereas DAXX loss lost 
prognostic significance for OS (209 versus 208 months, p=0.517). 
 
The 5-year and 10-year survival rates for ATRX-negative tumours were 54% 
and 0%, compared to 88% and 69% for ATRX-positive tumours.  Multivariate 
survival analysis demonstrated that lymphovascular invasion (p = 0.03), 
perineural invasion (p = 0.011), and loss of ATRX expression (p = 0.012) were 
independently associated with poorer overall survival.  Combined 
ATRX/DAXX expression was not an independent predictor of overall survival 
(p = 0.174) in this model - summarised in Table 3. 
 
The clinical and pathological associations of ATRX and DAXX loss are 
presented in Table 4. Tumours which were negative for either DAXX or ATRX 
were more common in patients >58 years of age (p = 0.013), were associated 
with higher Ki67 proliferative indices (p = 0.004), high grade (p = 0.017), nodal 
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involvement (p = 0.001), higher stage (p = 0.001), infiltrative borders (p = 
0.003) and lymphovascular invasion (p = 0.001). 
 
In view of a previous study suggesting that ATRX/DAXX loss was associated 
with better survival in patients presenting with metastatic disease [9], we 
performed further survival analysis on the 13 patients who initially presented 
with metastatic disease (2 of the 15 patients who initially presented with 
metastasis had unavailable ATRX/DAXX results; table 5). In this cohort, 
ATRX/DAXX-negative PanNETs with metastasis at presentation showed a 
trend towards improved overall survival (mean 169 months vs 83 months) 
compared to ATRX/DAXX-positive tumours, however the difference did not 
reach statistical significance (p=0.889).  Metastatic ATRX-negative tumours 
demonstrated a non-statistically significant trend towards worse overall 
survival (mean 17 versus 215.8 months, p=0.263) compared to ATRX-positive 
tumours.  All three patients with metastatic DAXX-negative tumours were alive 
with no metastasis at last follow up, however again this trend towards better 
survival did not reach statistical significance (p = 0.418 and 0.726).  
 
 
DISCUSSION 
In this large study of 113 unselected patients with PanNET, we demonstrated 
that loss of ATRX or DAXX as determined by IHC occurred in 25% of the 105 
assessable patients and was associated with poor overall survival in 
univariate analysis, but not in multivariate analysis because of a strong 
correlation with other adverse prognostic features.  Separate analysis of 
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ATRX and DAXX expression demonstrated that ATRX negativity was 
associated with poor overall survival (103 months versus 226 months) in both 
univariate (p = 0.0001) and multivariable analysis (p = 0.012) whereas DAXX 
loss by itself was not statistically significant.  Remarkably, no patients with 
ATRX-negative PanNETs survived 10 years.  Other independent variables 
associated with poorer survival in multivariate modelling included the 
presence of perineural invasion (p = 0.011) and lymphovascular invasion (p = 
0.03).   
 
Our findings are in keeping with four previous studies which have found 
ATRX/DAXX-negative PanNETs are associated with worse outcomes [16-19].  
Marinoni et al. found this association in two independent cohorts consisting of 
90 and 72 patients as did Singhi et al in a larger cohort of 321 patients [16, 
17].  Of note, although Pipinikas et al. found a similar association of poor 
survival for combined ATRX or AXX-negative PanNETs, when ATRX and 
DAXX loss were examined separately DAXX loss, but not ATRX loss, was 
associated with poor progression-free survival [18]. However we note that this 
was a study of a smaller cohort (53 PanNETs of whom 34 had clinical follow-
up). More recently, Roy et al [19] found genomic alterations in ATRX/DAXX as 
well as chromatin remodelling genes (ARID1A, SETD2) and CDKN2A gene 
were frequent in metastatic PanNET.  They subsequently, assessed alteration 
of these genes in a large cohort of primary PanNETs and found loss of 
function of at least one marker was detected in 81% of PanNETS and 
associated with poorer survival.  Univariate survival analysis found 
ATRX/DAXX loss correlated with poorer survival, similar to our study; loss of 
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HEK36me3, deletion of CDKN2A, but not loss of ARID1A was also associated 
with poorer survival.   However, similar to other three studies, Roy et al. did 
not address whether each gene alteration are independent prognostic factors 
of survival.   
 
In contrast to our findings, two studies have suggested that ATRX/DAXX-
negative PanNETs are associated with better survival [9,15]. These had some 
methodological and cohort differences which may explain the discrepant 
findings.  For example in Jiao et al’s study, patients with high stage disease 
(stage III/IV) were over-represented compared to our cohort, and indeed all 
patients with ATRX/DAXX-negative tumours (29 out of 68) presented with 
metastatic disease [9]. To investigate whether ATRX/DAXX loss may be 
associated with better prognosis in metastatic or advanced disease but worse 
prognosis in localized tumours, we therefore performed a subgroup analysis 
in the 13 patients with metastatic disease at presentation in our cohort and 
also found that there was a trend for ATRX/DAXX-negative tumours to be 
associated with longer survival.  Although this finding did not reach statistical 
significance (p = 0.889), it raises the intriguing possibility that ATRX/DAXX 
loss may be associated with poor survival in low stage tumours but better 
survival in high stage or metastatic tumours.  If this association is valid, we 
can only postulate that PanNETs diagnosed at advanced stage may be 
molecularly different to those diagnosed earlier and that other cancer 
pathways may play a more significant role in advanced PanNETs. Ultimately 
further studies would be required to confirm whether this is a true association 
and to investigate potential mechanisms. 
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Park et al [15] also found ATRX/DAXX-negative PanNETs (60 out of 76 
tumours) were associated with better overall survival in their unselected 
cohort recruited from a major teaching hospital.  However, compared to many 
other studies including our own which generally show a combined incidence 
of ATRX/DAXX loss of no more than 43% [8,9,16,17], the 79% incidence of 
ATRX/DAXX-negative PanNETs appears unusually high. We postulate that 
technical differences in antibody deployment and interpretation may account 
for this outlying result. For example Park et al [15] defined negative staining 
as ‘the presence of positive cytoplasmic staining with negative nuclear 
staining in the presence of positive internal control’.  In contrast in our, and 
most other studies, a negative result was interpreted as negative nuclear 
staining in the presence of positive internal control (endothelial, stromal or 
inflammatory cells), irrespective of cytoplasmic staining which we interpreted 
as non-specific and ignored.  This method of interpretation is supported by 
Marinoni’s study [16] which demonstrated a high correlation between 
ATRX/DAXX mutation status and loss of nuclear staining (irrespective of 
cytoplasmic staining) for ATRX/DAXX.   
 
In our study, ATRX loss on its own but not isolated DAXX loss was 
prognostically significant in PanNETs.  Previous study have found ATRX and 
DAXX were part of a common pathway of alternative lengthening of telomeres 
(ALT) associated with survival, hence most previous studies have not 
assessed ATRX and DAXX as independent prognostic factors [16,17].  It is 
worth noting that despite the initial recognition of DAXX as a pro-apoptotic 
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protein, it has recently been found to also have anti-apoptotic effects.  Various 
studies using cancer cell lines (prostate and ovarian cancer), have 
demonstrated that DAXX knockdown can result in increased autophagy, 
decreased angiogenesis, and reduced cell proliferation in tumour cells 
resulting in lack of tumour growth and progression [20,21]. In contrast, ATRX 
knockdown in in-vivo models of glioblastoma has been demonstrated to 
accelerate tumour growth and reduce survival in mice [22]. Future 
mechanistic studies would therefore be helpful to understand the different 
roles ATRX and DAXX play in the biological progression of PanNETs. 
 
We note that in this study the Ki67 proliferative index did not predict overall 
survival (p=0.788 for Grade 1 vs Grade 2 tumours). One potential reason for 
this and weakness of this study is that for n=29 (26%) of cases the 
proliferative index was only performed on TMA cores which may be less 
accurate than whole sections.  We also note that our primary endpoint was 
overall survival which may be a less accurate measure of the biology of these 
tumours than disease free survival given the relatively indolent nature of low 
grade PanNETS.  Interestingly in most large published cohorts, the overall (as 
opposed to the disease free) survival difference between Grade 1 and Grade 
2 PanNETs is usually small and often commonly not significant in multivariate 
analysis [23,24].  In fact in one recent large study of 274 patients[24], there 
was no difference in survival between Grade 1 and Grade 2 PanNETs using 
the then established WHO criteria of a cut off of ≤2% for proliferative index.  In 
fact in that study the 10-year overall survival of patients with Ki67 proliferative 
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index ≤2% was 80% - a trend to be worse than the 10 year survival of patients 
with a Ki67 2.1–5% which was 95% (P=0.487)[24]. 
 
In conclusion, in our study either ATRX or DAXX loss (which occurred in 25% 
of patients with PanNET) was associated with poor survival and adverse 
clinicopathological variables.  However, only isolated ATRX loss and not 
isolated DAXX loss was independently associated with overall survival. 
Interestingly the adverse prognostic effect of ATRX/DAXX loss was not 
present in patients presenting with metastasis and, in fact, in these patients 
ATRX/DAXX loss was associated with a trend toward better survival.  In view 
of its increasing availability in diagnostic pathology laboratories, ATRX 
immunohistochemistry in particular may therefore have a role as an 
independent prognostic biomarker in the routine management of patients with 
PanNET.   
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Figure legends 
Figure 1: ATRX and DAXX immunohistochemistry (IHC). 
A-C) Serial sections from an ATRX-positive (panel B) and DAXX-negative 
(panel C) tumour. Only nuclear staining is considered significant with 
cytoplasmic staining being ignored. For either DAXX or ATRX to be 
considered negative there is a requirement for unequivocal staining in non-
neoplastic cells which act as internal positive controls. Original magnifications 
400x.   
D-F) Serial sections from an ATRX-negative (panel E) and DAXX-positive 
(panel F) tumour. Again a little non-specific cytoplasmic staining is ignored 
and the need for positive internal controls is emphasized.  Original 
magnifications 400x.   
 
Figure 2: Kaplan-Meier survival curves. A) Overall survival of ATRX/DAXX-
positive versus -negative tumours. B) Overall survival of ATRX-positive versus 
-negative tumours. C) Overall survival of DAXX-positive versus -negative 
tumours. 
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Table 1. Clinicopathological features of PanNET in the cohort 
Clinicopathological variables 
n = 113 (%) 
Mean OS 
(months) P value 
Gender       
female 53 (47) 175 0.215 
male 60 (53) 222   
Age (median 58 years, mean 
57, range 18-87 months)       
≤58 59 (52) 211 0.461 
>58 54 (48) 173   
Type of surgery       
enucleation 17 (15) 206 0.941 
pancreatectomy 96 (85) 201   
Location       
head 39 (35) 152 0.005 
body/tail 67 (59) 231   
unknown 7 (6)     
Number of tumours       
single 91 (81) 203 0.495 
multiple (>1) 22 (19) 171   
Size (median 13mm, mean 
20mm, range 2-45mm)       
≤13mm 24 (21) 193 0.648 
>13mm 87 (77) 201   
unknown 2 (2)     
Tumour necrosis       
absent 107 (95) 212 0.022 
present 6 (5) 111   
Mitosis       
<2/10 HPF1 84 (74) 204 0.893 1 
2-20/10 HPF1 27 (24) 227   
>20/10 HPF 1 (1) 6   
unknown 1 (1)     
Ki67       
<3% 71 (63) 206 0.788 2 
3-20% 37 (33) 202   
>20% 3 (2.5) 26   
unknown 2 (1.5)     
2017 WHO grade       
grade 1 63 (56) 194 0.414 3 
grade 2 47 (42) 228   
grade 3 3 (2) 26   
Node involvement       
absent 84 (74) 209 0.306 
present 28 (25) 174   
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unknown 1 (1)     
Metastasis at presentation       
absent 97 (86) 208 0.172 
present 15 (13) 197   
unknown 1 (1)     
2017 AJCC stage       
I-II 73 (65) 214 0.153 
III-IV 39 (34) 185   
unknown 1 (1)     
Resection status       
clear 99 (88) 203 0.206 
involved 10 (9) 147   
unknown 4 (3)     
Tumour border       
circumscribed 82 (73) 209 0.001 
infiltrative 27 (24) 144   
unknown 4 (3)     
Vascular invasion       
absent 78 (69) 218 0.028 
present 34 (30) 182   
unknown 1 (1)     
Perineural invasion       
absent 104 (92) 208 0.025 
present 8 (7) 65   
unknown 1 (1)     
Hormone secreting        
absent 87 (77) 192 0.255 
present 24 (21) 223   
unknown 2 (2)     
Associated with hereditary 
syndrome       
absent 95 (84) 207 0.821 
present 18 (16) 169   
1 Mitosis of >20/10 hpf were excluded from analysis due to low numbers and all 
cases were censored. 
2 Ki67 >20% was excluded from analysis due to low numbers and all cases were 
censored. 
3 Grade 3 was excluded from analysis due to low numbers and all cases were 
censored. 
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Table 2.  Correlation of ATRX and DAXX IHC with overall survival 
Immunohistochemistry 
profile n = 105 
Mean OS 
(months) P value 
DAXX       
negative 16 209 0.517 
positive 88 208   
ATRX       
negative 10 103 0.0001 
positive 95 226   
Combined ATRX & DAXX       
    ATRX/DAXX negative 26 162 0.045 
    both positive 79 231   
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Table 3. Multivariate cox regression model for overall survival 
  Hazard ratio 
95% Confidence 
interval P value 
Location       
  head 1     
  body/tail 0.668 0.195-2.287 0.52 
Necrosis       
  absent 1     
  present 2.332 0.551-9.870 0.25 
Border       
  circumscribed 1     
  infiltrative 0.996 0.948-1.046 0.878 
Lymphovascular invasion       
  absent 1     
  present 3.694 1.132-12.051 0.03 
Perineural invasion       
  absent 1     
  present 11.823 1.781-78.499 0.011 
ATRX       
  positive 1     
  negative 16.982 1.882-153.238 0.012 
ATRX/DAXX       
  positive 1     
  negative 1.851 0.042-1.773 0.174 
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Table 4. Comparison between ATRX/DAXXXX negative and positive 
tumours 
  
ATRX/DAXX 
negative 
ATRX & 
DAXX 
positive 
P 
value 
ATRX 
negative    
n=10 
ATRX 
positive      
n=95 
P 
value 
  n=26 n=79         
Gender             
female 10 40 0.366 5 45 1.000 
male 16 39   5 50   
Age (median 58 months, 
average 57, range 18-87 
months)       
    
  
≤58 8 47 0.013 3 52 0.187 
>58 18 32   7 43   
Type of surgery             
enucleation 2 15 0.229 1 16 1.000 
pancreatectomy 24 64   
9 79 
  
Location             
head 8 29 0.809 5 32   
body/tail 16 46   4 58 0.288 
unknown 2 4   1 5   
Number of tumours       
    
  
single 24 62 0.147 9 77 0.685 
multiple (>1) 2 17   1 18   
Size (median 13mm, average 
20mm, range 2-45mm)       
    
  
≤13mm 2 17 0.147 1 18 0.685 
>13mm 24 62   9 77   
tumour necrosis             
absent 23 76 0.160 9 90 0.460 
present 3 3   1 5   
Mitosis             
<2/10 HPF1 17 62   8 71   
2-20/10 HPF1 9 16 0.291 2 23 0.902 
>20/10 HPF 0 1   0 1   
Ki67             
<3% 10 56   5 60   
3-20% 15 19 0.004 4 30 0.433 
>20% 0 3   0 3   
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unknown 1 1   1 2   
2017 WHO grade       
    
  
grade 1 9 49   6 52   
grade 2 17 27   4 40 0.831 
grade 3 0 3 0.017 0 3   
Node involvement       
    
  
absent 13 67 0.001 6 74 0.244 
present 13 12   4 21   
Metastasis at presentation       
    
  
absent 20 72 0.083 7 85 0.107 
present 6 7   3 10   
2017 AJCC stage             
I-II 9 61 0.001 3 67 0.015 
III-IV 17 18   7 28   
Resection status             
clear 21 73   8 86   
involved 5 5 0.116 2 8 0.475 
unknown 0 1   0 1   
Tumour border             
circumscribed 14 65   4 75   
infiltrative 12 12 0.003 6 18 0.013 
unknown 0 2      2   
Lymphovascular invasion       
    
  
absent 11 63 0.001 6 68 0.477 
present 15 16   4 27   
Perineural invasion       
    
  
absent 24 74 1.000 10 88 1.000 
present 2 5   0 7   
Hormone secreting with 
clinical syndrome       
    
  
absent 23 59 0.178 9 73 0.687 
present 3 20   1 22   
Associated with hereditary 
syndrome       
    
  
absent 24 66 0.348 8 82 0.633 
present 2 13   2 13   
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
Table 5. Correlation of ATRX and DAXX IHC with overall survival in patients 
presented with metastasis 
Immunohistochemistry 
profile n = 13 
mean OS 
(months) P value 
ATRX       
negative 3 17 0.263 
positive 10 215.8   
DAXX*       
    negative 3 N/A** 0.418 
    positive 9     
Combined ATRX & DAXX       
    ATRX or DAXX negative 6 169 0.889 
    both positive 7 83   
* One case had unavailable DAXX result 
**Mean survival was unable to be calculated because all 3 patients with DAXX negative 
tumour are still alive without recurrence. 
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Highlights 
 
 
ATRX and DAXX loss are mutually exclusive and occur in 25% of PNETs 
 
ATRX loss is associated with worse survival (103 months versus 226 months, 
p=0.0001) 
 
No patients with ATRX negative tumours survived 10 years 
 
ATRX and DAXX loss are associated with other adverse prognostic indicators 
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